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Application of nanoparticles has recently promising results for water insoluble agents like curcumin. In this study, we synthesized
polymeric nanoparticle-curcumin (PNPC) and then showed its efficiency, drug loading, stability, and safety. Therapeutic effects
of PNPC were also assessed on two cell lines and in an animal model of breast cancer. PNPC remarkably suppressed mammary
and hepatocellular carcinoma cells proliferation (𝑃 < 0.05). Under the dosing procedure, PNPC was safe at 31.25mg/kg and lower
doses. Higher doses demonstrated minimal hepatocellular and renal toxicity in paraclinical and histopathological examinations.
Tumor take rate in PNPC-treated group was 37.5% compared with 87.5% in control (𝑃 < 0.05). Average tumor size and weight
were significantly lower in PNPC group than control (𝑃 < 0.05). PNPC increased proapoptotic Bax protein expression (𝑃 < 0.05).
Antiapoptotic Bcl-2 protein expression, however, was lower in PNPC-treated animals than the control ones (𝑃 < 0.05). In addition,
proliferative and angiogenic parameters were statistically decreased in PNPC-treated animals (𝑃 < 0.05). These results highlight
the suppressing role for PNPC in in vitro and in vivo tumor growth models. Our findings provide credible evidence for superior
biocompatibility of the polymeric nanocarrier in pharmacological arena together with an excellent tumor-suppressing response.
1. Introduction
Curcumin (1,7-bis (4-hydroxy-3-methoxy-phenyl)-1,6-hep-
tadiene-3,5-dione; diferuloylmethane) is a natural, yellow,
and lipid-soluble compound extracted from Curcuma longa
plant with no discernible toxicity. Recent studies have shown
that curcumin, either alone or in combination with other
anticancer agents, has potent anticancer effects [1]. Curcumin
is water insoluble and is eliminated mostly unchanged and
partly altered in the gut. In preclinical and clinical studies,
oral administration of curcumin yields low plasma and
tissue concentrations. This may be due to low absorption,
rapid metabolism and elimination, and limited systemic
bioavailability [2]. To prevail over these weak points, different
ways were tested such as piperine [3], liposomal curcumin
[4, 5], and nanoparticle curcumin use [6, 7]. Application of
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nanoparticles has promising results for the poor water solu-
ble hydrophobic agents like curcumin. Feasible preparation
and use, size fitness, environmental sustainability, and shell
viability are all important factors for a suitable carrier [8].
According to some studies, encapsulated form of curcumin
improves its medical properties and solubility [9]. Previous
studies showed that dendrosome, a diblock nanostructure
made by oleic acid (OA) and polyethylene glycol (PEG, 400
Dalton) with anticancer and proapoptosis effects, is a suitable
option for curcumin encapsulation [10–12]. In the present
research, we used modified 2000 Dalton molecular weight
monomethoxy-PEG (mPEG) for curcumin encapsulation.
Recently our research group evaluated morphology and
physical behavior of mPEG
2000
-OA [13]. Based on CMC
measurement, this novel nanocarrier can be considered as an
appropriate drug delivery system for curcumin delivery in
cancer cells. A unique feature of mPEG
2000
-OA is the ease
with which the structure of their monomers can be varied
in order to provide suitable, inert drug porters for target
cells. In this study, we exploited mPEG
2000
-OA for curcumin
encapsulation as polymeric nanoparticle curcumin (PNPC)
and investigated its efficiency, drug loading, and stability with
more focus on clinical observations, hematological/blood
chemistry tests, and histological examinations. In addition,
PNPC’s protective and therapeutic effects were also assessed
in an animal model of breast cancer. Our results shed new
light on PNPC potential biocompatibility in in vitro and in
vivo biological systems.
2. Materials and Methods
2.1. Materials. Curcumin (>99%), doxorubicin hydrochlo-
ride, cyclophosphamide, ketamine, and xylazine were pur-
chased from Sigma Aldrich Co. (St. Louis, MO, USA). Mate-
rials for the polymeric nanocarrier (OM2000) preparation
including oleoyl chloride and methoxy polyethylene glycol
2000 (mPEG 2000) were got from Sigma-Aldrich Co. (St.
Louis, MO, USA). Chloroform and triethyl amine were
also purchased from Merck-Serono Company (Germany).
The human hepatocellular (HuH-7), mouse mammary (4T1)
carcinoma cell lines, and normal human fibroblast cells were
procured from Pasteur Institute of Iran (Pasteur Institute,
Tehran, Iran). Polyclonal mouse anti-rat/rabbit Bax, Bcl-2,
and CD31 antibodies (DAKO Corporation, USA) and rabbit
monoclonal antibody against Ki-67 (Thermo Fisher Scientific
Inc., San Jose, CA) were purchased.
2.2. The Study Design. Studies were conducted in five series
of experiments including (i) PNPC synthesis, (ii) PNPC
stability and drug loading, (iii) PNPC effects on cell viability
of mammary and hepatocellular carcinoma cells, (iv) PNPC
acute and chronic toxicity, and (v) PNPC protective and
therapeutic effects on animal model of breast cancer.
2.3. Animals. All animal studies have been conducted
according to relevant national and international guidelines of
the Weatherall report and Institutional Animal Care and Use
Committee (IACUC) of Tehran University of Medical Sci-
ences. Inbred female BALB/cmice (6–8 weeks old, purchased
from Iran Pasteur Institute) were maintained under 12-hour
dark and light cycle, with free access to food and water.
2.4. Polymeric Nanocarrier Synthesis. Polymeric nanoparticle
(PNP, OM2000) was synthesized by esterification of oleoyl
chloride (3.01 g, 0.01mol) and methoxy polyethylene glycol
2000 (20 g, 0.01mol) in the presence of triethyl amine (1.2 g,
0.012mol) and chloroform as solvent at 25∘C for 2 h (see
Supplemental Figure 1 in Supplementary Materials avail-
able online at http://dx.doi.org/10.1155/2015/824746). Triethyl
amine hydrochloride was filtered from organic phase. Chlo-
roform was then evaporated and OM2000 dried in a 40∘C
vacuum oven for 4 h with 96% purity. Fourier transform
infrared (FT-IR) spectroscopic measurements in the potas-
sium bromide (KBr) pellets were done using a Perkin-Elmer
spectrometer.The 1HNMR spectrumswere carried out using
Bruker 400MHZ in DMSO-d
5
.
2.5. Critical Micelle Concentration Determination. Critical
micelle concentration (CMC) of PNP was determined by
detecting shifts in the pyrene fluorescence absorbance spectra
[14]. In this regard, 3mL of pyrene solution (6 × 10−6M)
in acetone was added to a glass test tube and evaporated to
remove the solvent. Then, 5mL of PNP (0.005 to 1mg/mL)
was conjugated with phosphate-buffered saline (PBS; 0.01M,
pH 7.4) added to the glass test tubes to reach to 6 × 10−7M
pyrene final concentration. The solutions were vortexed and
conditioned at 37∘C overnight. Fluorescence excitation spec-
tra of pyrene (300–350 nm) were measured at an emission
wavelength of 390 nm with slit widths of 2.5 and 5.0 nm
(Perkin-Elmer Fluorimeter, USA) for excitation and emis-
sion, respectively. The fluorescence excitation shifts from 334
to 339 nm were used to determine CMC of the polymeric
nanocarrier.
2.6. PNPC Physical Properties. Dynamic light scattering
(DLS) and atomic force microscopy (AFM) were carried
out to evaluate alterations in the zeta-potential, particle size,
particle size distribution, shape, and polydispersity index
(PdI) of the polymeric nanoparticle [14–16]. Nanoparticle
zeta-potential and size distribution of PNPC (0.01M PBS,
pH 7.4) were analyzed by DLS (Zetasizer NanoZS, Malvern
Instruments, UK) using an argon laser beam at 633 nm and
90∘ scattering angle. To determine PNPC shape, a drop of
PNPC solution (0.05mg/mL) was placed on freshly cleaved
mica and was allowed to dry at room temperature. The
sample was then mounted on a microscope scanner and
imaged in semicontact mode with AFM (JPK Instruments
Co., Germany).
2.7. PNPC Encapsulation Efficiency and Drug Loading. In
this section, measurements were performed in triplicate.
Different concentrations of curcumin (2 to 25mg) in acetone
solutionweremixedwith 100mgnanocarrier in 3mLofwater
and rotated with rotary evaporator till acetone evaporation.
PNPC was filtered using 0.22𝜇m syringe filter to remove
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nonencapsulated curcumin and then lyophilized. To disrupt
micellar or vesicle structures, 10mg lyophilized PNPC was
dissolved in 1mL methanol and vortexed with ultrasonic
waves for 10min to ensure encapsulated curcumin release.
Curcumin concentration was then determined with spec-
trophotometer at 425 nm in comparison with methanol cali-
bration curve for curcumin. Drug loading (DL) and encapsu-
lation efficiency (EE) of curcumin/nanocarrier micelles were
finally quantified utilizing the following equation [15, 16]:
Drug loading content (%)
=
weight of curcumin in micelles
weight of micelles
× 100,
Encapsulation efficiency (%)
=
weight of micelled curcumin
weight of feeding curcumin
× 100.
(1)
2.8. PNPC Preparation. Curcumin (6mg) was dissolved in
acetone and added into nanocarrier solution (100mg/3mL
water) and then mixed and rotated with rotary evaporator
for acetone evaporation. PNPC was filtered using 0.22𝜇m
syringe filter to remove nonencapsulated curcumin. The
complex was then lyophilized and used for next experiments
[13].
2.9. Stability Assays. PNPC aqueous solution was kept at
4∘C for 24 h and ten months at dark room temperature.
Precipitation indicates PNPC instability, while clear solution
confirms its stability [17]. Dissolved lyophilized samples in
water were made by manual shaking without additional
heating or sonication. PNPC size and distribution were
compared with freshly prepared PNPC by DLS [18]. At the
end of the first week, curcumin loaded content and size
distribution of PNPC were compared with freshly prepared
PNPC by spectroscopy and DLS, respectively.
2.10. MTT Assay. HuH-7, 4T1, and normal fibroblast cell
lines were grown in Dulbecco’s modified Eagle’s medium
(DMEM; GIBCO, USA) containing 10% fetal bovine serum
(FBS; GIBCO, USA) at 37∘C in humid atmosphere. Cell
viability measured by MTT (3-[4,5-dimethylthiazol-2-yl] 2,
5-diphenyltetrazolium bromide) assay [19]. Curcumin stock
solution (100 𝜇M) in DMEM was prepared from 10mM
curcumin in methanol. Methanol percentage in the final
solution was lower than 0.4% v/v. Identical cell numbers (1 ×
106 cells) in 200𝜇L DMEM containing 10% FBS were seeded
in triplicate on 96-well plates and incubated overnight. Cells
were subsequently treated with various concentrations (0,
10, 20, 30, and 40 𝜇M) of PNPC, PNP alone, curcumin,
and doxorubicin (as positive control) for 24 h and 48 h.
Afterwards, 20𝜇L of MTT (5mg/mL) was added to each well
and incubated for an additional 4 h followedby adding 200 𝜇L
of dimethyl sulfoxide. Relative cell viability was then deter-
mined using a 96-well plate reader (TECAN, Switzerland) at
540 nm.
2.11. Dosing Procedure. One hundred sixteen BALB/c mice
were used to study the acute and chronic toxicity of PNPC
[20]. In acute toxicity protocol, 2000mg/kg of PNPC was
given as starting dose. Then, doses of 2000, 1000, 500, 250,
125, 62.5, 31.25, and 15.63mg/kg body weight of PNPC and
PNP were intraperitoneally injected. Animals were eutha-
nized after 24 h. In case of studying 24 h adverse reactions,
the dose was adjusted based on the average toxicity and the
last tolerated dose for the new group of mice. Organ damage,
histopathological findings, abnormal hematological/blood
chemical indices, reduced organ weight ratio, and body
weight changes were amongst the toxicity signs.
Based on the acute toxicity results, chronic toxicity was
carried out using doses of 125, 62.5, 31.25, and 15.63mg/kg
of PNPC and PNP for 7 consecutive days. The dose with no
adverse reactions during 24 h was assigned as the survival
dose. Survived animals were weighed on a daily basis and
euthanized one week later. Hematology, blood chemistry,
and histopathological tests were carried out. Vital organs
including heart, liver, spleen, lung, brain, and kidney were
excised and weighed.
2.12. Hematology, Blood Chemistry, and Histopathological
Tests. Animals were decapitated under general anesthesia to
evaluate hematology, clinical chemistry, and histopathology
parameters. Blood samples were taken for clinical chemistry
tests. Total leukocyte count (WBC), erythrocyte count (RBC),
platelets (Plt), hemoglobin (Hgb), hematocrit (Hct), mean
cell volume (MCV), mean corpuscular hemoglobin (MCH)
and mean corpuscular hemoglobin concentration (MCHC),
neutrophils, lymphocytes, eosinophils, and monocytes were
measured using an animal blood counter (Celltac; Nihon
Kohden, Tokyo, Japan). Plasma urea nitrogen (BUN), creati-
nine (Cr), sodium (Na), potassium (K), chloride (Cl), bicar-
bonate (HCO3−), calcium (Ca), magnesium (Mg), lactate
(Lac), osmolarity (Osm), and glucose (Glu) were determined
using CCX System (CCX WB; Nova Biomedical, USA).
Plasma alkaline phosphatase (ALP), albumin (ALB), total
bilirubin (T.Bil), direct bilirubin (D.Bil), gamma-glutamyl
transpeptidase (GGT), alanine transaminase (ALT), and
aspartate transaminase (AST)were alsomeasured (Autoanal-
yser Model Biotecnica, BT 3500, Rome, Italy). In addition,
liver, kidney, brain, lung, spleen, and heart tissue samples
were fixed and preserved in 4% buffered formaldehyde for
at least 24 h. Tissue blocks were prepared and evaluated for
histopathological changes.
2.13. Tumor Transplantation. Spontaneous mouse mammary
tumor (SMMT) was aseptically separated from the breast-
cancer-bearing BALB/c mice, cut into pieces of less than
0.3 cm3, and subcutaneously transplanted into the animals’
left flank under ketamine and xylazine (10mg/kg, i.p.) anes-
thesia [21].
2.14. PNPC Protective Effects on an Animal Model of Breast
Cancer. Sixteen mice were divided into two equal groups
of nontreated (control) and treated for the study of PNPC
protective effects on a typical animal model of breast cancer.
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PNPC was given for 24 days, from 3 days before to 21 days
after tumor transplantation. Animal survival rate and tumor
take rate were measured at the end of the study.
2.15. PNPC Therapeutic Effects on an Animal Model of Breast
Cancer. Twenty-four mice were equally divided into neg-
ative control, positive control, and PNPC groups to study
nanocurcumin therapeutic effects on mice breast cancer.
PNPC was given for 24 days after tumor transplantation
from day 14 up to day 38. In the positive control group,
doxorubicin (5mg/kg) and cyclophosphamide (2mg/mouse)
were intraperitoneally coadministered in three separate doses
for three consecutive weeks. Normal saline was also given
in the negative control group. Tumor volume was measured
weekly by a digital vernier caliper (Mitutoyo, Japan) and
reported according to the following formula [21]:
𝑉 =
1
6 (𝜋𝐿𝑊𝐷)
, (2)
where 𝐿 = length,𝑊 = width, and𝐷 = depth.
2.16. Histopathological Assay. The breast tumoral and adja-
cent nontumoral mucosal tissues were fixed in 10% formalde-
hyde, passaged, and embedded in paraffin. Paraffin blocks
were then sectioned by 3–5 𝜇m thickness for hematoxylin
and eosin (H&E) staining [22]. Slides were studied using
OLYMPUS-BX51microscope. Digital photos were takenwith
OLYMPUS-DP12 camera and graded by the Scarff-Bloom-
Richardson Scale [23].
2.17. Immunohistochemistry Examinations. Immunohisto-
chemistry was carried out on 3–5 𝜇m tissue sections taken
from the formalin-fixed paraffin blocks using avidin-biotin
immunoperoxidase method [24]. For tumor cells’ apoptotic
and angiogenic studies, sections were stained with polyclonal
mouse anti-rat/rabbit Bax, Bcl-2, and CD31 antibodies
(DAKO Corporation, USA) according to the manufacturer’s
instructions. Briefly, the paraffin sections were deparaffinized
with xylene and rehydrated through a series of descending
graded ethanol solutions. Slides kept into TBS-EDTA
buffer and put into a microwave oven for 15min at 90∘C.
Endogenous peroxidase activity was blocked by 0.3% H
2
O
2
buffer incubation for 15min. Biotinylated secondary antibody
and avidin-biotin complex with horseradish peroxidase were
applied followed by chromogen 3,3󸀠-diaminobenzidine
addition (Sigma Chemical).
To study tumor cell proliferative activity, sections were
treated with 3% (v/v) H
2
O
2
at room temperature, blocked
with 10% (v/v) goat serum or rabbit serum (Nichirei, Tokyo,
Japan), and incubated with a rabbit monoclonal antibody
against Ki-67 (Thermo Fisher Scientific Inc., San Jose,
CA). Sections were then incubated with biotinylated goat
anti-rabbit IgG (Nichirei) and a solution of streptavidin-
conjugated horseradish peroxidase (Nichirei) according to
the manufacturer’s recommendations.
Criteria used to evaluate Bax, Bcl-2, CD31, and Ki67
markers were based on the estimated proportion of positive
cells and estimated average staining intensity of positive cells
in cytoplasm (for Bax), membrane (for CD31), nucleus (for
Ki67), and membrane, cytoplasm or nucleus (for Bcl-2).
Semiquantitative score was adopted as follows [22, 24]:
no staining: 0;
faint/barely staining up to 1/3 of cells: 1,
moderate staining in 1/3 to 1/2 of cells: 2,
strong staining in more than 1/2 of cells: 3.
2.18. Statistical Analysis. Analysis of variance (ANOVA) and
Tukey’s post hoc tests were used for comparison between
groups. Two-tailed Student’s 𝑡-tests were used when compar-
ing two groups. Differences in tumor incidence (percentage
of animals with breast cancer) were analyzed by Fisher’s exact
probability test. Values were represented as mean ± SEM. 𝑃 <
0.05 was considered to be statistically significant. Statistical
analysis was done using SPSS statistical software version 14.0.
3. Results
3.1. The FT-IR Spectrum of the Polymeric Carrier. The FT-IR
spectrum of the polymeric carrier showed stretching band of
C–H aliphatic at 2889, 2947, and 2960 cm−1. C=O stretching
vibration of ester bands could be seen at 1736 cm−1. C–
H bending vibration of CH
2
and C–H bending vibration
of CH
3
can be seen in 1467 and 1343 cm−1, respectively.
C–O stretching vibration was at 1112 cm−1 as broad band
(Supplemental Figure 2).
3.2. The 1H NMR Spectrum of the Polymeric Carrier. Supple-
mental Figure 3 shows 1H NMR spectrum of the polymeric
carrier from 0 to 6.5 ppm in DMSO-d
5
. Saturated protons in
fatty ester were at 0.8, 1.2, 1.5, 2, and 2.3 ppm. CH
2
protons
between unsaturated bonds in linoleate and linolenate were at
2.6 ppm. Residual DMSO-d
5
1H NMR signal was at 2.5 ppm
(Supplemental Figure 3(a)). DMSO-d
5
water was in 3.3 ppm
as broad band. CH
3
protons of mPEG were in 3.2 ppm. CH
2
protons of mPEG ethylene oxide units were multipeaks in
3.5 ppm (Supplemental Figure 3(b)). CH
2
protons of mPEG
ethylene oxide connected to fatty acid chloride were at 4.1 and
4.2 ppm. C–H oleate, linoleate, and linolenate were in 5.3, 6.2,
and 6.4 ppm, respectively (Supplemental Figure 3(c)).
3.3. Critical Micelle Concentration of Polymeric Nanocarrier.
Concentration at crossover point in Figure 1 shows CMC
of nanocarrier at 339/334 nm intensity ratio and nanocarrier
concentration logarithm. As noted, CMC value is very low
near 0.03 g/L. With increasing nanocarrier concentration,
florescence intensity has significantly risen (Figure 1).
3.4. PNPC Physical Properties. The size, morphology, and
polydispersity of the nanoparticles were evaluated using
dynamic light-scattering technique (DLS) andAFMmethods
(Figure 2). The results show that two forms of particles
were produced in the process of synthesis, micelles and
polymersomes with the average size of 18.33 ± 5.32 nm and
99.44 ± 65 nm, respectively. The freshly prepared PNP with
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Figure 1: Determination of CMC of (a) pyrene excitation spectra shift and (b) four datasets from ten are displayed to simply show the below
and above CMC concentration when micelles developed. C: the concentration of polymeric nanoparticle (PNP).
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Figure 2: Morphology and particle size distribution of PNPC. (a) Red line shows average results of freshly prepared PNPC samples (0–25%
curcumin encapsulation in PNP). It shows three particle sizes, 18.3 ± 5.3, 65.5 ± 30, and 283 ± 112 nm. Green line shows average results of
PNPC samples after one week at 25∘C (0–25% curcumin encapsulation in PNP). It shows one particle size of 99.4 ± 42.6 nm. Blue line shows
average result of all samples with two sizes, 18.3 ± 5.3 (they seem to bemicelles) and 99.4 ± 65 nm (they seem to be polymersomes). (b) Atomic
forcemicroscopy (AFM) results. AFM image of redissolved PNPC after freeze-drying (0.05mg/mL) also showed two particle forms and sizes.
Smaller particles (<40 nm) seem to be micelles and larger particles (>40 nm) seem to be polymersomes.
different curcumin content (0–25%) weremonodisperse (PdI
= 0.332 ± 0.13), with three particle forms 53.5% micelles
(18.33 ± 5.3 nm), 38.8% polymersomes (65.5 ± 30 nm), and
7.5% polymersomes (283.6 ± 112 nm). However, after one
week of incubation at 25∘C, the particle forms changed to
be more monodisperse (PdI = 0.182 ± 0.072) with 100%
polymersomes (99.44 ± 42.56 nm). The results of AFM
analysis show that the shape of PNPC was in accordance
with DLS analysis (Figure 2(b)). However, compared to DLS
analysis, the AFM results show the larger size of PNPC
which can be attributed to the expansion of spherical micelles
or vesicles (polymersomes) in mica surface after drying its
solution. Moreover, the AFM results show that in PNPC
graph the z-dimensional (height) bar is smaller than X- and
Y-dimensional bars which support this claim (Supplemental
Figure 4).The PNPC is indeed stable in the presence of oleate
in this nanoformulation. The negative zeta-potential was
found to be −29.3 ± 5.2mV at concentration of 0.05mg/mL
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Figure 3: Encapsulation efficiency and drug loading of curcumin in PNPC. (a) Encapsulation efficiency (EE) and (b) drug loading (DL) of
curcumin.
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Figure 4: Stability test of curcumin/nanoparticle after one week at room temperature by DLS test.
(slightly higher concentration thanCMCpoint; 0.03mg/mL).
This low zeta-potential is at optimum range for stability of
PNPC and explains the reason of developing more uniform
size distribution (PdI = 0.182 ± 0.072) after one week at room
temperature [25, 26].
3.5. PNPC Encapsulation Efficiency and Drug Loading. The
average drug encapsulating efficiency and drug loading of
PNPC were 64 and 5.97 ± 2.1% (w/w), respectively. The
percentage of drug loading at different ratios of curcumin to
100mg of nanocarrier was plotted in Figure 3. Curcumin did
not precipitate at 6% loading after 10 months of incubation
(Supplemental Figure 5).
3.6. PNPC Stability. PNPC was stable more than 300 days
at 4∘C, although loading curcumin higher than 6% into
nanoparticles leads to some precipitation of curcumin (Sup-
plemental Figure 7). Lyophilized PNPC samples in water
dissolved by manual shaking without additional heating
or sonication. Then, size and distribution of PNP were
compared with freshly prepared PNPC by DLS (Fig-
ure 2(a)). After one week at 25∘C, as mentioned, PNPC
samples inclined to develop more uniform polymersomes
nanoparticles (PdI = 0.182 ± 0.072). Furthermore, spec-
troscopy analysis showed that one-third of curcumin in
curcumin/nanocarriers micelles (pH = 7.2) was conserved at
room temperature after one week (Figure 4).
3.7. PNPC Effects on HuH-7 and 4T1 Cell Lines. PNPC
significantly suppressed the proliferation of HuH-7 and 4T1
cancerous cells in a dose- and time-dependent manner in
comparison with curcumin and PNP groups (𝑃 < 0.05).
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Figure 5: Cytotoxic effects of PNPC on mouse mammary (4T1) and human hepatocellular (HuH-7) carcinoma cells. Cells were treated with
different concentrations of PNPC for 24 h (a) and 48 h (b) on 4T1 cell line and 24 h (c) and 48 h (d) on HuH-7 cell line. Data reported are
mean ± SD; ∗𝑃 < 0.05 compared to curcumin; PNPC = the polymeric nanoparticle curcumin; PNP = polymeric nanoparticles.
PNPC IC
50
for 4T1 cells was 29 𝜇Mwithin 24 h (Figure 5(a)),
which relatively reduced to 24 𝜇M in 48 h (Figure 5(b)).
In addition, PNPC IC
50
for HuH-7 cells was 25 𝜇M within
24 h (Figure 5(c)), which relatively reduced to 19𝜇M in
48 h (Figure 5(d)). We showed concentration about 48 and
40 𝜇M for IC
50
of free curcumin for 24 and 48 h, respectively.
Therefore, we showed that IC
50
of the free curcumin is signifi-
cantly higher than PNPC, and PNPC significantly suppressed
cell growth compared to free curcumin (𝑃 < 0.05). In
addition, no significant toxicitywas observed for voidmPEG-
OA nanocarrier (PNP) even at concentrations above the
40 𝜇M. PNPC was not toxic to normal human fibroblastic
cells (HFSF-PI3) [13], and this data is in accordance with
other researcher results reviewed by Ravindran et al. [27].
PNPC showed nonsignificant changes in comparison with
the positive control group. PNPC and doxorubicin had no
effect on normal human fibroblasts cells (data not shown).
3.8. PNPC Toxicity. The main toxicity signs to PNPC and
PNP in various doses are summarized in Tables 1 and 2
and Supplemental Tables 1–5. In acute toxicity groups, doses
of 2000, 1000, 500, and 250mg/kg of PNPC are associated
with death or severe poisoning symptoms. Additionally,
PNPC and PNP caused hematological, hepatocellular, and
renal toxicity at the acute dose of 125mg/kg (Table 1 and
Supplemental Table 1). Higher doses provoked severe adverse
reactions and death especially at 250mg/kg PNPC.
In the chronic toxicity groups, doses up to 62.5mg/kg
PNPC brought about no death, but at 125mg/kg PNPC, 2 out
of 6 mice died. Weight loss, diarrhea, imbalance, and ascites
were seen at 125mg/kg of PNPC after oneweek of consecutive
injections. Survived animals (31.25mg/kg and lower) had no
clinical differences compared with the control group. PNPC
showed remarkable safety rates up to 31.25mg/kg (Tables 1
and 2 and Supplemental Tables 1 and 2).
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Table 1: Acute toxicity effects of PNPC on hematological and blood chemical indices in mice.
Parameters
Groups
Control PNPC31.25mg/kg
PNPC
62.5mg/kg
PNPC
125mg/kg
Animal weight (g) 24.3 ± 2.2 25 ± 3.1 24.7 ± 2.5 23.2 ± 2.2
RBC (Millin/mm3) 6.08 ± 0.2 6.8 ± 0.8 7.2 ± 0.5 8.2 ± 0.4∗
HCT (%) 38.4 ± 1.7 37.7 ± 1.2 38.5 ± 2.5 42.5 ± 2∗
Hgb (g/dL) 10 ± 1.2 11.3 ± 1.8 11.7 ± 1.3 13.4 ± 1.6∗
MCV (FL) 51 ± 0.7 50.1 ± 0.8 49.3 ± 1.5 49.1 ± 1.2
MCH (pg) 16.5 ± 0.2 16.4 ± 0.3 15.5 ± 0.4 15.3 ± 0.3
MCHC (mol/L) 32.3 ± 0.7 32.4 ± 0.5 32.2 ± 0.4 32.5 ± 0.3
Plt (1000/mm3) 567 ± 50 546 ± 91 570 ± 45 540 ± 38
WBC (1000/mm3) 6.7 ± 0.8 8.7 ± 2 7.9 ± 1.5 8.1 ± 2.2
Neutrophils (%) 35.5 ± 2 36.6 ± 12 38 ± 5 38.2 ± 6
Monocytes (%) 2.1 ± 3 1.2 ± 0.9 3.1 ± 1 2.1 ± 0.8
Lymphocytes (%) 53.5 ± 6.4 52 ± 9 57.2 ± 5 57 ± 4
Na (mM/L) 150.3 ± 2.9 146.5 ± 3.3 154.2 ± 2.1 157.1 ± 1.5∗
K (mM/L) 5.2 ± 0.5 5.8 ± 1.3 6.1 ± 1.7 8.2 ± 2.2∗
Cl (mM/L) 111 ± 4 117 ± 3 114 ± 2 117 ± 3∗
HCO3− (mM/L) 22.6 ± 3.2 17.3 ± 1.6 17.5 ± 2.2 16.3 ± 2.7∗
Osm (mOsm/kg) 307 ± 4.7 307 ± 5.2 312.2 ± 7 320 ± 8∗
Ca (mM/L) 0.72 ± 0.14 0.63 ± 0.1 0.65 ± 0.2 0.66 ± 0.3
Mg (mM/L) 0.29 ± 0.04 0.30 ± 0.03 0.25 ± 0.04 0.31 ± 0.03
Glu (mg/dL) 194 ± 33 204 ± 48 182 ± 30 176 ± 25
Lac (mM/L) 5.4 ± 1.2 5.2 ± 1.3 5.2 ± 2 5.7 ± 1.8
Urea (mg/dL) 21.2 ± 2.6 21.3 ± 3.6 26 ± 5 43 ± 7∗
Cr (mg/dL) 0.48 ± 0.08 0.51 ± 0.07 0.55 ± 0.07 0.92 ± 0.12∗
AST (U/L) 455 ± 45 538 ± 85 777 ± 80 1280 ± 152∗
ALT (U/L) 68 ± 8.8 70.6 ± 8.7 86 ± 21 258 ± 86∗
ALP (U/L) 763 ± 50 794 ± 67 825 ± 36 1187 ± 92∗
GGT (U/L) 5.5 ± 0.5 — — 6.2 ± 0.6
ALB (mg/dL) 3 ± 0.2 — — 2.8 ± 0.4
T.BIL (mg/dL) 0.5 ± 0.03 — — 0.47 ± 0.05
D.BIL (mg/dL) 0.35 ± 0.05 — — 0.32 ± 0.04
Values are means ± SEM. ∗𝑃 < 0.05 compared to control. PNPC = the polymeric nanoparticle curcumin, RBC = red blood cell, HCT = hematocrit, MCV
= mean corpuscular volume, MCH = mean corpuscular hemoglobin, MCHC = mean corpuscular hemoglobin concentration, WBC = white blood cells, Plt
= platelets, Na = sodium, K = potassium, Cl = chloride, HCO3− = bicarbonate, Osm = osmolarity, Ca = calcium, Mg = magnesium, Cr = creatinine, Lac =
lactate, Glu = glucose, AST = aspartate transaminase, ALT = alanine transaminase, ALP = alkaline phosphatase, GGT = gamma-glutamyl transpeptidase, ALB
= albumin, T.BIL = total bilirubin, and D.BIL = direct bilirubin.
Hematological markers were measured by a complete
blood count analysis. No inflammatory responses were seen
in acute and chronic toxicity groups since total leukocyte
counts remained within normal range (Tables 1 and 2 and
Supplemental Table 1). In addition, significant increases in
RBC, Hct, and Hgb were seen in acute 125mg/kg PNPC
and chronic 62.5mg/kg PNPC groups compared to control
animals (𝑃 < 0.05) (Table 1 and Supplemental Table 1).
Na, K, and Cl were also statistically escalated, while HCO3−
drastically decreased in acute 125mg/kg PNPC (Table 1)
and chronic 62.5mg/kg PNPC-treated mice compared with
control groups (𝑃 < 0.05) (Table 2).
Plasma BUN and Cr levels were measured for kidney
function assessment, while ALP, T.Bil, D.Bil, GGT, ALB, ALT,
and AST were done for liver function evaluation. BUN and
Cr were significantly higher in animals of acute 125mg/kg
PNPC (Tables 1 and 2) and chronic 62.5mg/kg PNPC groups,
compared to control animals (𝑃 < 0.05) (Table 2 and
Supplemental Table 2). Furthermore, liver function tests
showed drastic increases in AST, ALT, andALP levels in acute
125mg/kg PNPC group (Table 1 and Supplemental Table 1)
and chronic 62.5mg/kg PNPC group (Table 2 and Supple-
mental Table 1) compared to control mice (𝑃 < 0.05). On the
other hand, albumin level significantly lowered at 62.5mg/kg
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Table 2: Chronic toxicity effects of PNPC on hematological and blood chemical indices and the organs weight percentage in mice.
Parameters
Groups
Control PNPC15.63mg/kg
PNPC
31.25mg/kg
PNPC
62.5mg/kg
Animal weight (g) 24.3 ± 2.2 24 ± 3.2 23.3 ± 3.4 18.3 ± 2.7∗
RBC (Millin/mm3) 6.08 ± 0.08 6.3 ± 0.07 6.9 ± 0.3 7.7 ± 0.4∗
HCT (%) 38.4 ± 1.7 36.6 ± 2.1 37.4 ± 1.2 40.3 ± 3.2
Hgb (g/dL) 10 ± 1.2 12 ± 1.1 9.8 ± 0.9 12.3 ± 1
MCV (FL) 51 ± 0.7 52.8 ± 0.6 50.4 ± 2 49.5 ± 1.5
MCH (pg) 16.5 ± 0.2 17.3 ± 0.3 15.7 ± 0.9 15.6 ± 0.5
MCHC (mol/L) 32.3 ± 0.7 32.8 ± 0.4 32 ± 0.7 32.2 ± 0.6
Plt (1000/mm3) 567 ± 50 519 ± 75 539 ± 53 594 ± 41
WBC (1000/mm3) 6.7 ± 0.8 6.9 ± 1 6.5 ± 1.8 7.7 ± 2.1
Neutrophils (%) 32.5 ± 2 41 ± 8 38.5 ± 11 42 ± 9
Monocytes (%) 2.1 ± 3 4.4 ± 2.1 1.8 ± 1 3.8 ± 2.2
Lymphocytes (%) 66.5 ± 6.4 53 ± 11 60.8 ± 5.8 51 ± 13
Na (mM/L) 150.3 ± 2.9 149.7 ± 3.2 151.2 ± 3.8 157.4 ± 1.5∗
K (mM/L) 5.2 ± 0.5 5.7 ± 1.6 4.9 ± 0.4 4.3 ± 0.8
Cl (mM/L) 111 ± 4 112.2 ± 2.1 112.7 ± 1.8 115.5 ± 2.3
HCO3− (mM/L) 22.6 ± 3.2 16.7 ± 4.9 19.9 ± 3.2 18.9 ± 2.7
Osm (mOsm/kg) 307 ± 4.7 301.3 ± 12 306.9 ± 8.2 315.8 ± 7
Ca (mM/L) 0.72 ± 0.14 0.61 ± 0.14 0.74 ± 0.07 0.97 ± 0.6
Mg (mM/L) 0.29 ± 0.04 0.30 ± 0.02 0.32 ± 0.04 0.35 ± 0.03
Glu (mg/dL) 194 ± 33 174 ± 31 172 ± 40 212 ± 30
Lac (mM/L) 5.4 ± 1.2 4.8 ± 1 5.1 ± 1.1 4.3 ± 1.5
Urea (mg/dL) 21.2 ± 2.6 19.4 ± 3.2 20 ± 2.6 24.5 ± 3.8
Cr (mg/dL) 0.48 ± 0.08 0.42 ± 0.05 0.53 ± 0.03 0.98 ± 0.08∗
AST (U/L) 455 ± 45 423 ± 64 503 ± 33 585 ± 36∗
ALT (U/L) 68 ± 8.8 72.3 ± 5.9 76.3 ± 12 92.3 ± 5∗
ALP (U/L) 763 ± 50 633 ± 83 666 ± 85 207 ± 23∗
GGT (U/L) 5.5 ± 0.5 — 5.9 ± 0.8 6.4 ± 1
ALB (mg/dL) 3 ± 0.2 — 3.4 ± 0.6 2.3 ± 0.3∗
T.BIL (mg/dL) 0.5 ± 0.03 — 0.47 ± 0.13 0.56 ± 0.1
D.BIL (mg/dL) 0.35 ± 0.05 — 0.38 ± 0.08 0.34 ± 0.05
% body weight
Heart 0.52 ± 0.06 0.47 ± 0.04
Liver 6.3 ± 0.35 4.2 ± 0.26∗
Spleen 0.43 ± 0.05 0.58 ± 0.07
Lung 0.73 ± 0.09 0.71 ± 0.07
Kidney 1.53 ± 0.15 1.46 ± 0.22
Brain 1.12 ± 0.11 1.19 ± 0.15
Values are means ± SEM. ∗𝑃 < 0.05 compared to control. PNPC = the polymeric nanoparticle curcumin, RBC = red blood cell, HCT = hematocrit, MCV
= mean corpuscular volume, MCH = mean corpuscular hemoglobin, MCHC = mean corpuscular hemoglobin concentration, WBC = white blood cells, Plt
= platelets, Na = sodium, K = potassium, Cl = chloride, HCO3− = bicarbonate, Osm = osmolarity, Ca = calcium, Mg = magnesium, Cr = creatinine, Lac =
lactate, Glu = glucose, AST = aspartate transaminase, ALT = alanine transaminase, ALP = alkaline phosphatase, GGT = gamma-glutamyl transpeptidase, ALB
= albumin, T.BIL = total bilirubin, and D.BIL = direct bilirubin.
in chronic PNPC group compared to control animals (Table 2
and Supplemental Table 2). Liver and kidney weights were
decreased but spleen weight increased in 125mg/kg PNPC
and PNP groups compared to controls groups (Table 2). It
seems that the liver and the kidney were the target organs for
the polymeric carrier toxicity in high doses.
In this study, we also injected 31.25mg/kg PNPC for 7
consecutive days and animals were euthanized at the end of
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Figure 6: Light microscopic analysis of organs impressed from PNPC (125mg/kg). Mild Kupffer cells hyperplasia and sinusoidal distention
in favor of congestion were seen in the liver tissue [(A) (20x), (a) (40x)]. Moderate congestion, sinusoidal dilatation with preserved white
lymphoid pulp was seen in the spleen tissue [(B) (20x), (b) (20x)]. The glomeruli were unremarkable but mild peritubular congestion and
proteinaceous cast formations were noted in some kidney tubules [(C) (20x), (c) (40x)].
2, 4, and 12 weeks. No adverse reactions observed in hemato-
logical, blood chemical, and histological examinations in this
protocol (Supplemental Table 3).
We also compromised the toxicity of PNPC and PNP
each other. In the acute toxicity, no significant difference
was observed in hematological and blood chemical exami-
nations in various doses of PNPC and PNP (Supplemental
Table 4). But in the chronic groups, high BUN and AST
levels and low albumin serum level were seen at 62.5mg/kg
PNP group compared to PNPC animals (Supplemental
Table 5).
3.9. Histopathology Examinations. In order to obtain an
accurate diagnosis of PNPC and PNP toxicity onmicroscopic
levels, major organs were histopathologically evaluated.
Compared with control, animals treated with 125mg/kg
PNPC and PNP developed slight abdominal ascites, kidney,
liver, and spleen congestion after one-week consecutive injec-
tions. AST, ALT, ALP, and GGT drastic increases in these
groups may be assumed as liver dysfunction. These changes
were also congruent with elevated renal biomarkers. In the
liver, mild Kupffer cells hyperplasia and sinusoidal distention
in favor of congestion were seen (Figure 6(A)). In addition,
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we observed moderate congestion, sinusoidal dilatation with
preserved white lymphoid pulp in the spleen tissue (Fig-
ure 6(B)). In the kidney, the glomeruli were unremarkable
but mild peritubular congestion and proteinaceous cast
formations were noted in some tubules (Figure 6(C)). In all
of the histopathological examinations we observed minimal
hepatic and renal toxicity. No histological abnormality was
found in other major organs such as the brain, the heart, and
the lung. Additionally, no significant pathologic changes were
found in themajor organs of animals treatedwith 31.25mg/kg
PNPC and lower doses compared with the control group, so
31.25mg/kg dose was ruled out as the toxic dose.
3.10. PNPC Protective Effects on Animal Breast Cancer. In the
protective study, PNPC was injected for 24 consecutive days,
from 3 days before to 21 days after tumor transplantation.
At the end of the study, the tumor take rate was at 37.5%
in comparison with control group (87.5%; 𝑃 < 0.05).
Additionally, PNPC-treated mice had a greater survival rate
of at least 20 weeks after tumor transplantation compared to
the control animals who died by the end of the eighth week.
3.11. PNPC Therapeutic Effects on Animal Breast Cancer.
PNPCwas given for 24 days after tumor transplantation from
day 14 up to day 38 to evaluate the therapeutic effects of PNPC
onmice breast cancer. At the end of the third week, the tumor
disappeared in 3 and the tumor volume decreased in 3 and
increased in other two mice in PNPC group. Animals gained
weight in PNPC group compared to the negative control.The
average tumor volume and weight were significantly less than
the negative control in the second and thirdweeks after PNPC
treatment (𝑃 < 0.05). The mean final tumor volume reached
approximately 390mm3 and 1420mm3 in PNPC-treated and
control animals, respectively (Figure 7). The mean tumor
volume and weight in the positive control group showed
insignificant changes with PNPC group.
3.12. The Tumor Type and Characterization. Spontaneous
mouse mammary tumor was invasive ductal carcinoma,
malignant cells with hyperchromatic and polymorphism
nuclei, and a low to moderate rate of mitosis. Tumor cell
infiltration was observed in the surrounding tissues and nests
of carcinoma cells with grade II/III based on Scarff-Bloom-
Richardson Scale (Supplemental Figure 6).
3.13. Metastases. At the end of the study, all animals under-
went routine surgery. There were no signs of metastasis in
major organs of both PNPC-treated and control groups.
3.14. Immunohistochemistry Examinations. Immunohisto-
chemistry examinations in PNPC-treated animals showed
increased proapoptotic Bax protein expression in breast
tumor in comparison with control (Figure 8 and Supple-
mental Figure 7A). Antiapoptotic Bcl-2 protein expression
conceivably lowered after PNPC therapy (Figure 8 and
Supplemental Figure 7B). In addition, treatment with PNPC
caused a significant reduction in Bcl-2 activity and Bcl-2/Bax
ratio compared to the control group (𝑃 < 0.05).
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Figure 7: The polymeric nanoparticle curcumin effects on tumor
size (cm3) in mouse mammary tumor. The positive control: “dox-
orubicin and cyclophosphamide were used as positive control.” Data
reported are mean ± SD; ∗𝑃 < 0.05 compared to negative control;
PNPC = polymeric nanoparticle curcumin.
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Figure 8:Thepolymeric nanoparticle curcumin effects on immuno-
histochemical markers in mouse mammary tumor. Data reported
are mean ± SD; ∗𝑃 < 0.05 compared to control; PNPC = polymeric
nanoparticle curcumin.
Angiogenesis also dramatically decreased in breast
tumors of PNPC-treated animals. CD31 activity reduced in
PNPC-treated mice tumors compared to control animals
(Figure 8 and Supplemental Figure 7C). Moreover, most of
the tumor cells represented high Ki67 marker in control
group. The mean proliferative cell number in PNPC-treated
mice was lower than the control group (𝑃 < 0.05) (Figure 8
and Supplemental Figure 7D).
4. Discussion
Our study showed that the polymeric nanocarrier is a
negative, amphipathic, and biodegradable polymer suitable
for drug delivery. They are new types of biocompatible
polymeric chains taken from plant fatty acids suitable for
curcumin bioavailability. Figure 1 shows that, with increasing
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nanocarrier concentration to more than CMC, the flores-
cence intensity has significantly risen. This is due to the self-
aggregation of micelle blocks and development of hydropho-
bic compartment inside themicelles and subsequent increase
of pyrene florescence. Additionally, CMC low value indicates
micelles thermodynamic stability which is enhanced after
extreme in vivo dilution and may improve circulation time
compared to surfactant micelles [14]. Another advantage of
this nanocarrier is its small size which provokes passive
targeting of the tumor tissues by increasing permeability and
retention. Moreover, the stability of encapsulated curcumin
in the polymeric nanoparticle is quite appropriate comparing
with free curcuminwhich degrades to about 90% after 30min
[28]. Therefore, this nanocarrier conserves curcumin from
decomposition and degradation and can be considered as an
appropriate drug carrier for in vitro and in vivo experiments.
The major goal of our study was to develop polymeric
nanoparticle curcumin as an applicable strategy in can-
cer treatment. Toxicity is a crucial factor for nanoparticle
safety in nanomedicine arena. Understanding of various
determinants of nanoparticle toxicity helps establishing suit-
able strategies for selecting appropriate compositions to
develop biocompatible and efficacious polymeric carriers
in nanomedicine requests. In our study, the polymeric
nanoparticle curcumin significantly suppressed proliferation
of human and mouse carcinoma cells in vitro. Based on
hematological, blood chemical, and histopathological exam-
inations, minimal hepatic and renal toxicity was seen with
high PNPC doses. In addition, in vivo results showed that
tumor incidence, weight, and size were significantly declined
in PNPC-treated animals. PNPC also induced proapoptotic
Bax protein expression and reduced antiapoptotic Bcl-2
protein levels relative to the control group. Moreover, pro-
liferative and angiogenic markers were lowered in PNPC-
treated animals. These findings point to the features of the
polymeric carrier as a promising drug delivery system for
cancer therapy.
In the present study, we showed that monotherapy with
PNPC at high doses (250mg/kg) and polymeric nanocarrier
alone caused the animal acute death. Daily administration of
PNPC and PNP at higher doses (125mg/kg) for one week
has also been life-threatening. Macroscopic changes such
as ascites, weight loss, and imbalance together with other
untoward sequels like splenomegaly were also seen in some
animals. Histological examinations revealed macrophage
infiltration and splenic hyperplasia. Sodium and K+ levels
were significantly increased at high PNPC doses compared to
the control animals.This indicates that fluid balance is some-
how affected by PNPC administration and is in agreement
with ascites and diarrhea observed in some animals at the
same dose groups. RBC, Hct, and Hgb levels were drastically
increased at 62.5mg/kg and higher doses compared to the
controls. Increased Cr level may be due to Cr release from
damaged muscular cells [21]. We are not sure about the
reversibility of PNPC and PNP induced blood chemistry
and hematological changes since it is beyond the scope of
the present study. Significant decrease in liver weight and
albumin level together with increased ALT, AST, ALP, and
GGT in PNPC- or PNP-treated animals points to the hepatic
effects of high doses and may by induced by polymeric
nanocarrier metabolism. Nevertheless, striking liver changes
on the above mentioned parameters were seen in animals
taking very high PNPC and PNP doses.These outcomes may
have been primary or secondary effects from nanocarrier in
some major organs such as liver, kidney, and spleen. Our
results support this hypothesis that mPEG may trigger liver
dysfunctions together with other organ toxicities [29, 30].
Our important finding is that the polymeric nanocarrier
dramatically increased tumor-suppressing effects of cur-
cumin both in cell culture and in a typical animal model of
breast cancer. Our results also showed that tumor incidence,
weight, and size were significantly declined in PNPC-treated
group. Fairly complete tumor regression after 24 days is a
dramatic finding with PNPC treatment observed in some
animals. We also observed a decrease in tumor incidence
as well as tumor size in both protective and PNPC-treated
mice compared to the control group. Tumor incidence
and size are indicators of proliferation and angiogenesis
[31]. Changes in tumor growth characteristics observed in
animals treated with PNPC suggest antiproliferative and
antiangiogenic effects of PNPC. Lower tumor incidence and
smaller tumor size may have been attributed to the direct
effects of PNPC owing to its potential antiproliferative and
antiangiogenic roles or its indirect strong oxidative response
[32]. It should be noted that other pathways involved in
the protective effects of PNPC are being pursued in our
laboratory.
Apoptosis role in breast carcinogenesis has been exten-
sively studied. It has been shown accordingly that resis-
tance to apoptosis in premalignant breast epithelial cells can
develop breast tumors [33]. In order to gain insight into
the mechanisms involved in apoptosis induction mediated
by PNPC in breast cancer, we studied its effects on the
expression of Bcl-2 and Bax proteins under in vivo situations.
Many genetic alterations of breast cancer are actually derived
from an imbalance between pro- and antiapoptotic members
of the Bcl-2 family [34]. It has generally been established
that oncoprotein Bcl-2 duels with its counteracting twin,
a protein known as Bax. Overexpression of Bax promotes
cell death; conversely, Bcl-2 functions as a suppressor of
apoptosis. A decrease in Bcl-2/Bax ratio has been considered
as a reliable indicator of the overall propensity of a cell to
undergo apoptosis [34]. In the present study, PNPCdecreased
Bcl-2/Bax ratio by suppressing Bcl-2 expression and Bax
stimulation.This may be indicative of the Bcl-2 family role in
apoptosis inductionmediated by PNPC inmice breast cancer
[35, 36]. These findings reveal a new therapeutic potential
for PNPC in different tissues malignancies via apoptosis
induction.
In addition, tumor growth noticeably depends on angio-
genesis where simultaneous enhances in the tumor vascula-
ture supply nutrients and oxygen to the growing neoplastic
cells is required [37]. Growth and progression of breast
tumor as well as growth of most of other cancers are
angiogenesis-dependent processes. High angiogenic activity
in the primary tumor seems to be well correlated with
untoward sequels in patients suffering from breast cancer.
Breast cancer is considered to be an angiogenic carcinoma
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due to high expression of proangiogenic factors [38]. We
found in vivo anticarcinogenic properties of nanocurcumin
as effective as in vitro antiproliferative and antiangiogenic
effects of curcumin. These compounds presumably change
the balance of pro-and antiangiogenic factors in tumor tissues
and fix the effective delivery system of therapeutic drugs to
tumor cells in a larger scale. Our results provide support for
a potential therapeutic role of PNPC in breast cancer via
their antiangiogenic and antiproliferative properties. In fact,
it seems that the polymeric nanocarrier increases tumor cell
access to curcumin and in turn, it causes tumor cells death.
In some previous reports, polymeric nanocarriers were
used for curcumin tissue delivery. Bisht et al. (2007) syn-
thesized a polymeric nanoparticle of curcumin (50–100 nm
range) in an encapsulated formulation utilizing micellar
aggregates of cross-linked and indiscriminate acrylic copoly-
mers of N-isopropylacrylamide (NIPAAM) with N-vinyl-2-
pyrrolidone (VP) [15]. An ideal drug delivery platform must
be biodegradable, biocompatible, and free from incidental
adverse effects. Bisht’s nanocarriers are nondegradable and
harmful to health due to NIPAAM, VP, and poly(ethylene
glycol) monoacrylate monomers use. But, in our nanocarrier
form, fatty acids with biodegradable and biocompatible
properties were adopted to produce the least health harmful
effects unless in very high doses. In addition, Anand et
al. (2010) used PLGA-poly-ethylene glycol nanoparticles to
deliver encapsulated curcumin with 97.5% efficiency but
low drug loading [39]. Our data reveals for the first time
that nanopolymeric compounds not only boost curcumin
solubility and uptake in cell lines but also increase its toxicity
on cancer cells. This issue with the biodegradable ability
shows that polymeric carriers are unique host cell drug in
animal models as per the following aspects.
(a) They are inexpensive, neutral, nontoxic, biodegrad-
able, and easy to use.
(b) Pharmaceutical agents can create a weak structural
combination helping their easy cellular separation.
(c) Although nanocarriers are biodegradable, they are
stable and resistant not only in dry environments but
also in fluids with low temperature.
5. Conclusion
In summary, we showed that PNPC is effective in sup-
pressing tumor growth both in vitro and in vivo. Tumor
growth in PNPC-treated mice was significantly suppressed
and/or almost completely stopped at the end of the treat-
ment. Our results also suggested PNPC appropriate dose
(31.25mg/kg/daily for 3 weeks). Lower doses effectiveness or
fewer PNPC shots are currently being investigated in our
laboratory. The present study provides persuasive evidence
for polymeric nanocarrier superior biocompatibility in phar-
macological arena which in turn can reduce anticancer drug
side effects with excellent tumor-suppressing response.
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